ArticleAbdominal radiology (New York)2026
Deep learning in enhanced CT imaging: predicting invasion depth of rectal adenocarcinoma.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aims to develop and evaluate a deep learning model, RectoDepthAI, that leverages enhanced CT images to accurately assess the tumor invasion depth in rectal adenocarcinoma, distinguishing between early-stage (submucosal or muscularis propria invasion) and advanced-stage (pararectal tissue or adjacent structure invasion) tumors.
methodUtilizing a dataset of 934 patients, RectoDepthAI integrates ResNet-18 for spatial feature extraction and Long Short-Term Memory (LSTM) for sequential processing of venous phase CT slices. Data management involved preprocessing, augmentation, and 5-fold cross-validation; evaluation metrics included AUC, accuracy, sensitivity, and specificity; interpretability was enhanced via Gradient-weighted Class Activation Mapping (Grad-CAM).
resultsIn its evaluation phase, RectoDepthAI was assessed over five rounds of training and validation, demonstrating robust performance with an average AUC of 0.883, accuracy of 84.1%, sensitivity of 87.0%, and specificity of 80.0%. Grad-CAM enhanced the interpretability of diagnostic predictions.
conclusionRectoDepthAI emerges as a promising tool for non-invasive staging of rectal adenocarcinoma, improving diagnostic precision and supporting clinicians in treatment decision-making.
Indexed as
Identifiers
41524989What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.